Barry Greenberg, MD
Enriched profileDistinguished Professor of Medicine; Director, Advanced Heart Failure Treatment Program · University of California, San Diego
Barry Greenberg is Distinguished Professor of Medicine; Director, Advanced Heart Failure Treatment Program at University of California, San Diego. OpenAlex indexes 718 publications with 40,987 citations (h-index 100); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Advanced Heart Failure and Transplant Cardiology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Barry H. Greenberg, MD, is Distinguished Professor of Medicine at University of California, San Diego (UC San Diego Health / UCSD School of Medicine). The public record shows 718 publications with 40,987 citations (h-index 100), centered on Heart Failure Treatment and Management, Cardiovascular Function and Risk Factors, Alzheimer's disease research and treatments. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 25 companies, 2 NIH-funded awards (2000–2012).
- Most recent indexed publication: 2026 · Journal of the American Heart Association
- Top research focus: Heart Failure Treatment and Management
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 25 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 366.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
Sponsor: Rocket Pharmaceuticals Inc.
- A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)
Sponsor: Rocket Pharmaceuticals Inc.
- Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone
Sponsor: Johns Hopkins University
Industry payments
Updated 27 Aug 2026
25 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year20253 payments
- Madrigal PharmaceuticalsProgram year202519 payments
- Merck Sharp & Dohme LLCProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
80.4%Beta blocker24.5%Carvedilol63%Metoprolol Succinate30%Metoprolol Tartrate8%Part D<11 patientsAldosterone antagonist (MRA)15.6%Spironolactone75%Eplerenone25%Part D<11 patientsMetabolism & gastrointestinal
14.5%SGLT2 inhibitor12.3%Jardiance100%Part D≥24 patientsPotassium supplement2.2%Potassium Chloride100%Part D<11 patientsBlood & clotting
5.1%Factor Xa inhibitor5.1%Eliquis100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
2 NIH research awards on record, funded 2000–2012 per NIH RePORTER. The latest:
- RCT Targeting Cognition in Early Alzheimer's Disease by Improving Sleep with Trazodone (Rest)
Johns Hopkins University
FY2024$858,987R01AG071522 - RCT Targeting Cognition in Early Alzheimer's Disease by Improving Sleep with Trazodone (Rest)
Johns Hopkins University
FY2023$710,750R01AG071522 - RCT Targeting Cognition in Early Alzheimer's Disease by Improving Sleep withTrazodone (Rest)
Johns Hopkins University
FY2023$99,527R01AG071522
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Angiotensin-Neprilysin Inhibition and Renal Outcome in Men and Women With Heart Failure.
Journal of the American Heart Association
Article2026 - Analysis of the PARAGON-HF Study Results Using Win Ratio.
Circulation. Heart failure
Clinical Trial2024 - Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea.
American journal of cardiovascular drugs
Article2024 - Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea.
Journal of Korean medical science
Article2024
Most-cited works
by citation count (OpenAlex)- 01Depression in Heart Failure1,502 citations2006
- 02
- 03
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/profile/Barry-Greenberg-4
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
hfsa.digitellinc.com/hfsa/speakers/view/3
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hfsa.digitellinc.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- Board Certified
Internal Medicine (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - Board Certified
Cardiovascular Disease (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Editorial & leadership roles
journal and society appointments- Founding member and past President
Heart Failure Society of America (HFSA)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hfsa.digitellinc.com ↗ - Associate Editor
JACC: Heart Failure
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jacc.org ↗ - Editorial Board
Journal of Cardiac Failure
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hfsa.org ↗
Awards & honors
honors on the public record- 2026 Top 10 Clinical Research Achievement Award
Clinical Research Forum (for gene therapy study on Danon disease published in New England Journal of Medicine)
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →today.ucsd.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hfsa.org ↗
Media & interviews
press, podcasts and appearances- Medscape CME program "Optimizing Outcomes With Pharmacologic Management in ADHF"
hosted/presented segment on pathophysiology of acutely decompensated heart failure
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medscape.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ravindra Mehta, MD
University of California, San Diego
Anthony Demaria, MD
University of California, San Diego
Arthur Kavanaugh, MD
University of California, San Diego
Joachim Ix, MD
University of California, San Diego